Upstream Cell Line Development

  1. CHO Fed-batch Portfolio: Cellvento® And EX-CELL® Advanced Media And Feeds 3/11/2021

    Cellvento® and EX-CELL® Advanced cell culture media supports consistent growth and performance from development to production. Get the enhanced performance, assured regulatory compliance and the security of supply necessary in today’s biopharmaceutical environment.

  2. Solentim VIPS® PRO 10/3/2022

    Watch to learn how VIPS PRO optimizes your workflow productivity and provides complete confidence in single cell seeding and clonality assurance

  3. STUDIUS™ & ICON™: Data-Driven Workflow For The Development Of Modern Cell-Based Therapies 2/28/2022

    Learn how these two new products work to provide a new data-driven workflow for the development of modern cell-based therapies.

  4. VIPS™ For Cell Therapy: Updates 9/30/2022

    Watch to learn about the latest developments to VIPS™ which address the needs of cell therapy companies moving towards GMP manufacturing.

  5. SAFC Cell Culture Solutions 4/13/2021

    The SAFC® portfolio is a full-service provider for all your upstream process development and cGMP manufacturing needs. Discover all the  capabilities of our SAFC® cell culture solutions and which of our products are the perfect fit for your project.

  6. What's The Best Way To Choose A Mycoplasma Detection Strategy? 1/26/2023

    Mycoplasma contamination of cell cultures is a common and costly problem in biopharma, but ddPCR™ technology can help you save time and reduce risks of false positives.

  7. Nunc Standard Closed Cell Factory System 2/2/2022

    This clean and closed system is designed to provide consistent and high-quality results to enhance your adherent cell culture processes. This ready-to-use system will help you quickly develop and scale up your processes with standard components for supply assurance.

  8. Increase The Titer Of A Difficult To Express Molecule 12/11/2019

    What happens if you have a promising molecule but can’t engineer a cell line to deliver the titer needed to support clinical development?  A low process titer may render the molecule, such as an antibody, too costly to manufacture and unsuitable for continued investment. Learn how our client achieved a nearly 4-fold titer increase.

  9. Defining A New Ecosystem For Cell Line Development 3/7/2022

    In this presentation learn more about Solentim ICON™, the world’s first benchtop system for characterizing high productivity clones and STUDIUS™ software, the new standard for cell line development.

  10. Navigating The Workflow From Process Development To GMP Manufacturing For Making Clonal iPSC-Derived Master Cell Banks 3/7/2022

    In this video, we present data for optimizing choices of which combinations of GMP-compatible matrix, dissociation reagents, and media can best be employed for single cell cloning of iPSCs in process development.